San Francisco treatment choices
A practical way to compare ibogaine models with regulated, locally available care for opioid and stimulant use disorders—without treating uncertainty as proof.
Start with the decision
Ibogaine is often discussed as a single intervention. In practice, people may encounter very different settings, screening practices, follow-up plans, and legal arrangements.
For opioid use disorder, methadone and buprenorphine are established medications with a substantial evidence base and regulated delivery pathways. Extended-release naltrexone is another medication option that may fit some circumstances after opioid-free initiation.
Ibogaine is not an approved treatment in the United States. By contrast, locally available treatment can include licensed prescribers, opioid treatment programs, behavioral health care, and emergency support.
Medication choice, co-occurring conditions, current substance use, and cardiac risk can all matter. A regulated setting does not remove risk, but it provides defined standards, escalation pathways, and continuity of care.
A comparison is more useful when it includes realistic follow-up: ongoing medication, counseling when wanted, overdose prevention, practical support, and a plan for a return to use.
Regulated care first
For many people with opioid use disorder, it makes sense to first assess regulated options available in San Francisco. The federal overview of medications for substance use disorders describes methadone, buprenorphine, and naltrexone as medication approaches used in care for opioid use disorder.
For stimulant use disorder, treatment planning may include evidence-based psychosocial care, attention to mental and physical health, and support that can continue over time. There is no single comparison that fits every person; goals, prior treatment experience, housing, work, family responsibilities, and other health conditions can change the practical fit.
Our broader San Francisco ibogaine treatment context is designed to keep legal status, research, safety questions, and realistic choices in view together. For an explanation of how this resource approaches claims and uncertainty, see the principles behind our independent guidance.
Evidence and legal status
Ibogaine has been studied in limited contexts, but study interest does not make it an approved or routine treatment in the United States. The U.S. Drug Enforcement Administration lists ibogaine as a Schedule I controlled substance in its drug scheduling framework.
“A useful comparison separates documented findings from promises made around an intervention.”
That distinction matters when evaluating travel-based programs or informal referrals. A program’s language may describe a medicalized experience without creating the safeguards, accountability, or continuity that come with regulated local treatment. Background on the compound itself is available in the ibogaine reference overview, but treatment decisions deserve discussion with appropriately qualified local professionals.
Research and travel
Clinical research has formal enrollment rules. Travel for an experimental intervention may involve a private arrangement in another jurisdiction, with variable oversight and aftercare.
Use the ClinicalTrials.gov study registry to identify registered studies, then review the listed purpose, eligibility criteria, location, sponsor, contact method, risks, and whether the study is recruiting. A listing is not a guarantee of benefit or eligibility.
Ask what medical screening occurs, who handles urgent complications, how medication interactions and cardiac concerns are assessed, what the plan is after returning to San Francisco, and what records will be available to the person’s local care team.
Ask whether the option can support ongoing care rather than a single event. The care-navigation topics covered here can help organize questions about access, safety, and next steps without promoting a particular provider.
A grounded priority
When opioid or stimulant use is creating immediate risk, when there are health concerns, or when support is needed now, locally available regulated treatment and urgent services deserve priority. Experimental options should be considered with clear-eyed attention to evidence, legal status, safety planning, and continuity—not as a substitute for those basics.
Review safety and risk questions